{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:49:07Z","timestamp":1785908947549,"version":"3.56.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273315"],"award-info":[{"award-number":["82273315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital of Sichuan University","doi-asserted-by":"publisher","award":["ZYGD23023"],"award-info":[{"award-number":["ZYGD23023"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0756"],"award-info":[{"award-number":["2024NSFSC0756"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.117041","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:00:56Z","timestamp":1781773256000},"page":"117041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity"],"prefix":"10.1016","volume":"185","author":[{"given":"Yusha","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyueer","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccell.2015.03.007","article-title":"The journey from discoveries in fundamental immunology to cancer immunotherapy","volume":"27","author":"Miller","year":"2015","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2026.117041_bb0015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.117041_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117041_bb0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1245\/s10434-008-0252-0","article-title":"CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma","volume":"16","author":"Sano","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","article-title":"Targeting CD24 as a novel immunotherapy for solid cancers","volume":"21","author":"Yang","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.intimp.2026.117041_bb0035","doi-asserted-by":"crossref","first-page":"1174789","DOI":"10.3389\/fimmu.2023.1174789","article-title":"CD24-Siglec interactions in inflammatory diseases","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117041_bb0040","article-title":"Siglec10-an immunosuppressor and negative predictor of survival prognosis in gliomas","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2026.117041_bb0045","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3389\/fimmu.2020.01324","article-title":"Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10","volume":"11","author":"Yin","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-021-01222-y","article-title":"Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology","volume":"15","author":"Song","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117041_bb0055","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00262-023-03491-7","article-title":"CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer","volume":"72","author":"Yang","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/imm.13847","article-title":"Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies","volume":"173","author":"Hazra","year":"2024","journal-title":"Immunology"},{"issue":"7769","key":"10.1016\/j.intimp.2026.117041_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030660","article-title":"Characterization of a novel third-generation anti-CD24-CAR against ovarian Cancer","volume":"20","author":"Klapdor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12094-021-02707-5","article-title":"Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance","volume":"24","author":"Murali","year":"2022","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0080","first-page":"240","article-title":"IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24\/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy","volume":"6","author":"Li","year":"2023","journal-title":"Antib Ther."},{"issue":"20","key":"10.1016\/j.intimp.2026.117041_bb0085","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1111\/febs.16880","article-title":"CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners","volume":"290","author":"S\u00f6hngen","year":"2023","journal-title":"FEBS J."},{"issue":"26","key":"10.1016\/j.intimp.2026.117041_bb0090","article-title":"Nano-LYTACs for degradation of membrane proteins and inhibition of CD24\/Siglec-10 Signaling pathway","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci (Weinh)."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0095","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2026.117041_bb0100","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.4049\/jimmunol.178.10.6227","article-title":"CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117041_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123159","article-title":"Targeting CD24 in Cancer immunotherapy","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117041_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.117041_bb0115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.intimp.2026.117041_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: newest frontier for Cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117041_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110238","article-title":"Breaking barriers: animal viruses as oncolytic and immunotherapeutic agents for human cancers","volume":"600","author":"Gazal","year":"2024","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.intimp.2026.117041_bb0130","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/JVI.02722-06","article-title":"Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain","volume":"81","author":"Hesse","year":"2007","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.intimp.2026.117041_bb0135","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"82","author":"Menotti","year":"2008","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0140","article-title":"Oncolytic adenovirus inhibits TNBC tumor growth\/metastasis in mice by targeting TGFB and overexpressing GM-CSF","volume":"33","author":"Nh\u00e0n","year":"2025","journal-title":"Mol Ther Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41417-024-00853-w","article-title":"Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC","volume":"32","author":"Ye","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.117041_bb0150","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/j.1460-2075.1990.tb08143.x","article-title":"Amino-terminal domain of NF1 binds to DNA as a dimer and activates adenovirus DNA replication","volume":"9","author":"Gounari","year":"1990","journal-title":"EMBO J."},{"issue":"6444","key":"10.1016\/j.intimp.2026.117041_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/365355a0","article-title":"An alternative pathway for transcription initiation involving TFII-I","volume":"365","author":"Roy","year":"1993","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.intimp.2026.117041_bb0160","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s00018-012-1055-9","article-title":"CD24 controls Src\/STAT3 activity in human tumors","volume":"69","author":"Bretz","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0165","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1570163814666170818125036","article-title":"Involvement of CD24 in multiple Cancer related pathways makes it an interesting new target for Cancer therapy","volume":"18","author":"Eyvazi","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.intimp.2026.117041_bb0170","article-title":"Lyn is involved in CD24-induced ERK1\/2 activation in colorectal cancer","volume":"11","author":"Su","year":"2012","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2026.117041_bb0175","article-title":"Human DNA virus exploitation of the MAPK-ERK cascade","volume":"20","author":"JK","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117041_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2024.200277","article-title":"E4orf1: the triple agent of adenovirus - Unraveling its roles in oncogenesis, infectious obesity and immune responses in virus replication and vector therapy","volume":"17","author":"G\u00f6ttig","year":"2024","journal-title":"Tumour Virus Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117041_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trecan.2023.09.012","article-title":"Integrating innate and adaptive immunity in oncolytic virus therapy","volume":"10","author":"DePeaux","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.intimp.2026.117041_bb0195","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8(+) T cell subsets in antitumor immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.intimp.2026.117041_bb0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.omto.2022.03.006","article-title":"IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity","volume":"25","author":"El-Sayes","year":"2022","journal-title":"Mol Ther Oncolytics."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117041_bb0215","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omto.2021.02.007","article-title":"Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes","volume":"20","author":"Labani-Motlagh","year":"2021","journal-title":"Mol Ther Oncolytics."},{"key":"10.1016\/j.intimp.2026.117041_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic virus-based cytokine expression to improve immune activity in brain and solid Tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol Ther Oncolytics."},{"issue":"12","key":"10.1016\/j.intimp.2026.117041_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009473","article-title":"Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.117041_bb0230","first-page":"2113","article-title":"An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment","volume":"110","author":"Li","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0235","article-title":"Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models","volume":"33","author":"Yates","year":"2025","journal-title":"Mol Ther Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117041_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117041_bb0245","doi-asserted-by":"crossref","first-page":"1183285","DOI":"10.3389\/fimmu.2023.1183285","article-title":"The biological roles of CD24 in ovarian cancer: old story, but new tales","volume":"14","author":"Gu","year":"2023","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.intimp.2026.117041_bb0250","doi-asserted-by":"crossref","first-page":"55663","DOI":"10.18632\/oncotarget.10971","article-title":"CD24 promoted cancer cell angiogenesis via Hsp90-mediated STAT3\/VEGF signaling pathway in colorectal cancer","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41392-023-01683-2","article-title":"Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0260","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.intimp.2026.117041_bb0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117041_bb0270","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.117041_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576310","article-title":"Shp1 loss enhances macrophage effector function and promotes anti-tumor immunity","volume":"11","author":"Myers","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117041_bb0280","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.4049\/jimmunol.166.9.5567","article-title":"CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains\/rafts-mediated signaling system","volume":"166","author":"Suzuki","year":"2001","journal-title":"J. Immunol."},{"issue":"39","key":"10.1016\/j.intimp.2026.117041_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202502758","article-title":"Signal transducer nanoparticles enable Siglec-10\/G blockade immunotherapy for breast cancer treatment","volume":"37","author":"Meng","year":"2025","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0290","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12964-025-02486-4","article-title":"Genetically platform presenting CD24 ScFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment","volume":"23","author":"Zhou","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"10","key":"10.1016\/j.intimp.2026.117041_bb0295","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00262-023-03488-2","article-title":"SIGLEC10(+) macrophages drive gastric cancer progression by suppressing CD8(+) T cell function","volume":"72","author":"Guo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"45","key":"10.1016\/j.intimp.2026.117041_bb0300","article-title":"Siglec-G suppresses CD8(+) T cells responses through metabolic rewiring and can be targeted to enhance tumor immunotherapy","volume":"11","author":"Yin","year":"2024","journal-title":"Adv Sci (Weinh)."},{"key":"10.1016\/j.intimp.2026.117041_bb0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.virol.2016.12.011","article-title":"Viral exploitation of the MEK\/ERK pathway - a tale of vaccinia virus and other viruses","volume":"507","author":"Bonjardim","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2026.117041_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1264983","article-title":"Influenza a virus replication has a stronger dependency on Raf\/MEK\/ERK signaling pathway activity than SARS-CoV-2","volume":"13","author":"Hoffmann","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"13","key":"10.1016\/j.intimp.2026.117041_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136946","article-title":"Repurposing anticancer drugs targeting the MAPK\/ERK Signaling pathway for the treatment of respiratory virus infections","volume":"25","author":"Liu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01413-20","article-title":"Prohibitin-1 contributes to cell-to-cell transmission of herpes simplex virus 1 via the MAPK\/ERK Signaling pathway","volume":"95","author":"Watanabe","year":"2021","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117041_bb0325","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/0008-5472.CAN-05-1484","article-title":"Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny","volume":"66","author":"Sch\u00fcmann","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.117041_bb0330","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/emboj\/20.6.1310","article-title":"Adenovirus-activated PKA and p38\/MAPK pathways boost microtubule-mediated nuclear targeting of virus","volume":"20","author":"Suomalainen","year":"2001","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.intimp.2026.117041_bb0335","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117041_bb0340","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:22:32Z","timestamp":1785907352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926008878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"alternative-id":["S1567576926008878"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117041","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"rSiglec-10(V set) armed oncolytic adenovirus improves the effects of virotherapy through enhancing oncolysis and antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117041"}}